PropThink: Catalyst Licenses New Candidate Ahead of November Data Release

PropThink: Catalyst Licenses New Candidate Ahead of November Data Release

[ACN Newswire] – By Jake KingCatalyst Pharmaceutical Partners (NASDAQ:CPRX) climbed as much as 18% ahead of the bell Wednesday after the company announced that it licensed the rights to an orphan drug for Lambert-Eaton … more

View todays social media effects on CPRX

View the latest stocks trending across Twitter. Click to view dashboard

Share this post